Neogenomics (NEO) Total Current Liabilities (2010 - 2026)

Neogenomics (NEO) has reported Total Current Liabilities for 17 consecutive years, with $84.6 million the latest figure, recorded in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $84.6 million, down 69.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $84.6 million (down 69.76% YoY), and the FY2025 annual result was $88.3 million, down 70.69% from the prior year.
• Total Current Liabilities was $84.6 million for Q1 2026 at Neogenomics, down from $88.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $301.2 million in Q4 2024 and troughed at $76.7 million in Q1 2024.
• Average Total Current Liabilities over 5 years is $136.8 million, with a median of $92.9 million recorded in 2023.
• The widest YoY moves for Total Current Liabilities: up 264.61% in 2025, down 70.69% in 2025.
• Over 5 years, Total Current Liabilities stood at $89.9 million in 2022, then advanced by 7.09% to $96.3 million in 2023, then jumped by 212.8% to $301.2 million in 2024, then tumbled by 70.69% to $88.3 million in 2025, then fell by 4.2% to $84.6 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $84.6 million in Q1 2026, $88.3 million in Q4 2025, and $97.9 million in Q3 2025.